NeuroScios GmbH is a contract research organization with a 30-year expertise in CNS drug development. The company offers an accelerated track from molecule to clinic, supporting the development of new treatments for a range of CNS diseases including Alzheimer’s disease, Parkinson’s disease, orphan neurodegenerative disorders, cerebrovascular diseases, and psychiatric diseases. They aim to optimize the chance of success by leveraging their profound knowledge of requirements such as pharmacology, ADME, toxicology, regulatory issues (IND/CTA), and clinical trials. Additionally, the company focuses on networking with the most experienced and reliable service providers, designing individualized development plans, and providing an outstanding network of KOLs in different fields of CNS diseases. Founded in 2013, NeuroScios GmbH boasts an international experience and fast reaction time, positioning itself as a valuable player in the healthcare and pharmaceutical industries.
There is no investment information
No recent news or press coverage available for NeuroScios GmbH.
We care about your data, and we'd love to use cookies make your experience better.
